SURVYR

INO

Inovio Pharmaceuticals, Inc.
$1.01
+$0.01 (1.00%)Oct 20 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-77%-54%-30%-6%+17%Oct 2025Oct 2026Apr 202652w high $2.7252w low $0.56
INOSPY
Wall St. Highest PT $4.00 (+296.0%) Wall St. Avg PT $3.17 (+213.5%)
$1$2$3$4$5POC $1Hi $4Avg $3
Underwater Drawdown %Max DD -74.6%Current -61.2%
0.0%-74.6%
Relative Strength vs SPY-74.9% vs SPYUnderperforming
+103%0%-103%
1W
+$0.01 (1.00%)
1M
−$0.23 (18.55%)
3M
−$0.09 (8.18%)
6M
−$0.12 (10.62%)
YTD
−$0.73 (41.95%)
1Y
−$1.46 (59.11%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
3 analysts · mean score 2.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$1.01
Average target$3.17
+$2.16 (+213.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$2.50
Median$3.17
High$4.00
12-month Wall Street target range
Recent analyst rating changes · 8
Upgrade
2026-08-13 · Jefferies upgraded INO from Hold to Buy
Reiterated
2026-08-03 · Piper Sandler reiterated Overweight on INO
Reiterated
2026-06-01 · HC Wainwright & Co. reiterated Neutral on INO
Reiterated
2025-11-14 · Piper Sandler reiterated Overweight on INO
Reiterated
2025-08-14 · HC Wainwright & Co. reiterated Neutral on INO
Initiated
2025-07-09 · Piper Sandler started covering INO at Overweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$104.4M
P/E (next 12 months, estimated)-2.3
52-week range$0.56 – $2.72
Dividend yieldNo dividend
Analyst consensusBuy (3)
Average analyst price target$3.17 (+214%)

What they do

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for INO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

INO earningsNext report in 13 days
Next report
Tue Nov 10, 2026Time not confirmed
EPS consensus-$0.20 range -$0.20–-$0.19
Revenue consensus$0 3 analysts
Last 4 quarters · EPS vs estimate
Aug 12, 2026-$0.24est -$0.24+0.6%In line with estimates
May 13, 2026-$0.31est -$0.33+4.7%Above estimates
Mar 12, 2026-$0.28est -$0.34+19.6%Above estimates
Nov 10, 2025-$0.87est -$0.48−82.8%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 01:31:46 ET
24-1125-0325-0525-0825-1126-0326-0526-08-1.130.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
PR Newswire · Oct 20
Rating changes
Upgrade
2026-08-13 · Jefferies upgraded INO from Hold to Buy
Reiterated
2026-08-03 · Piper Sandler reiterated Overweight on INO
Reiterated
2026-06-01 · HC Wainwright & Co. reiterated Neutral on INO
Reiterated
2025-11-14 · Piper Sandler reiterated Overweight on INO
Reiterated
2025-08-14 · HC Wainwright & Co. reiterated Neutral on INO
Initiated
2025-07-09 · Piper Sandler started covering INO at Overweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 01:31:46 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026